Connection
Wells Messersmith to Trastuzumab
This is a "connection" page, showing publications Wells Messersmith has written about Trastuzumab.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.183 |
|
|
|
-
Lakhani NJ, Chow LQM, Gainor JF, LoRusso P, Lee KW, Chung HC, Lee J, Bang YJ, Hodi FS, Kim WS, Santana-Davila R, Fanning P, Squifflet P, Jin F, Kuo TC, Wan HI, Pons J, Randolph SS, Messersmith WA. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 12; 22(12):1740-1751.
Score: 0.183